^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MAGEA3 overexpression

i
Other names: MAGE Family Member A3, Melanoma-Associated Antigen 3, MAGE-3 Antigen, Antigen MZ2-D, CT1.3, Cancer/Testis Antigen Family 1, Member 3, Melanoma Antigen Family A3, Cancer/Testis Antigen 1.3, MAGE3, HIP8, HYPD, Melanoma Antigen Family A, 3, MGC14613, MAGEA6, MAGEA3
Entrez ID:
8ms
Cancer testis antigen MAGEA3 in serum and serum-derived exosomes serves as a promising biomarker in lung adenocarcinoma. (PubMed, Sci Rep)
Further analysis signified that the expression of MAGEA3 mRNA was positive correlation with neutrophil, macrophages M2, dendritic cells resting, and eosinophilic, but negatively correlated with B cells, plasma cells, CD8 + T cells, CD4 + T cells, Th17 cells, macrophages and dendritic cells. Collectively, our results suggested that the MAGEA3 expression in mRNA and protein were upregulated in LUAD, and MAGEA3 could be used as a diagnostic biomarker and immunotherapy target for LUAD patients.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • MAGEA4 (Melanoma antigen family A, 4) • MAGEA3 (MAGE Family Member A3)
|
MAGEA3 overexpression • MAGEA4 overexpression
1year
Expression Pattern of Tumor-associated Antigens in Neuroblastoma: Association With Cytogenetic Features and Survival. (PubMed, Cancer Diagn Progn)
Multivariate analysis confirmed Survivin as independent marker for poor survival, and PHOX2B and MAGEA1 for better survival. High expression of TH, PHOX2B, and MAGEA1 genes are favorable prognostic factors for OS and EFS, whereas high expression of Survivin is associated with an increased risk of relapse or progression.
Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CD276 (CD276 Molecule) • BIRC5 (Baculoviral IAP repeat containing 5) • CTAG1B (Cancer/testis antigen 1B) • PRAME (Preferentially Expressed Antigen In Melanoma) • MAGEA3 (MAGE Family Member A3) • MAGEA1 (MAGE Family Member A1) • PHOX2B (Paired Like Homeobox 2B)
|
MYCN amplification • BIRC5 expression • BIRC5 overexpression • MAGEA3 overexpression
1year
Canadine inhibits epithelial mesenchymal transformation of HPV-negative cervical cancer. (PubMed, Tissue Barriers)
In addition, the inhibition of EMT due to the reduction of endogenous MAGEA3 by Canadine was also offset by the overexpression of exogenous MAGEA3. The study concludes that Canadine inhibits EMT of cervical cancer by inhibiting MAGEA3.
Journal
|
MAGEA3 (MAGE Family Member A3)
|
MAGEA3 overexpression
1year
First report of a novel NTRK3-IGDCC3 fusion in uterine sarcoma and clinical outcome under targeted therapy with the NTRK-inhibitor Larotrectinib (DGHO 2023)
Adjuvant single-agent Doxorubicin had been applied until in September 2020 a CT scan had revealed extensive multifocal recurrent disease. Thus, second line Docetaxel and Gemcitabine had been initiated before rapid progressive disease after two cycles prompted salvage surgery... We report the case of a patient with uterine sarcoma harboring a newly described NTRK3 gene fusion partner IGDCC3 that shows a rapid clinical response to treatment with LARO.
Clinical • Clinical data • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • HRD (Homologous Recombination Deficiency) • NTRK (Neurotrophic receptor tyrosine kinase) • MAGEA3 (MAGE Family Member A3) • MAGEA1 (MAGE Family Member A1)
|
NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • HRD • MAGEA3 overexpression • NTRK positive • NTRK fusion
|
Vitrakvi (larotrectinib) • gemcitabine • docetaxel • doxorubicin hydrochloride